TOKYO, JAPAN (August 8, 2023)--The Global Health Innovative Technology (GHIT) Fund is pleased to announce today to welcome an R&D-driven company Fujirebio Holdings Inc. (hereinafter “Fujirebio HD” and headquartered in Tokyo) to join GHIT as a new associate partner.

“We are excited to be working with Fujirebio HD to solve global health challenges and to help fight infectious diseases around the world. We expect that Fujirebio HD's expertise especially in in vitro diagnostics solutions will drive innovation in product development for tuberculosis, malaria, and neglected tropical diseases (NTDs). We are also confident that we will be able to support the expansion of Fujirebio HD's partnerships both domestically and globally,” said Dr. Osamu Kunii, CEO of the GHIT Fund.

Mr. Goki Ishikawa, President and CEO, Fujirebio HD said, “We have decided to join GHIT since we empathize the concept of its Mission “leveraging Japanese innovation to fight against infectious diseases through partnerships”. Our participation in GHIT enables us to utilize our R&D efforts in the fight against infectious diseases around the world, which leads us to a further contribution to global health.”

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/neuro.